Imunon (IMNN) News Today $0.84 0.00 (-0.33%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$0.82 -0.02 (-1.94%) As of 05:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Imunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCOApril 22, 2025 | markets.businessinsider.comIMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual MeetingApril 21, 2025 | globenewswire.comImunon Stock Short Interest Report | NASDAQ:IMNN | BenzingaApril 20, 2025 | benzinga.comImunon files to sell 10M shares of common stock, warrantsApril 5, 2025 | markets.businessinsider.comIMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…March 28, 2025 | msn.comFDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatmentMarch 25, 2025 | msn.comImunon finalizes Phase 3 study design with FDA for IMNN-001March 25, 2025 | markets.businessinsider.comIMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian CancerMarch 24, 2025 | globenewswire.comIMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…February 28, 2025 | msn.comQ4 2024 Imunon Inc Earnings CallFebruary 28, 2025 | uk.finance.yahoo.comImunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial ChallengesFebruary 28, 2025 | finance.yahoo.comImunon, Inc.: IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19February 27, 2025 | finanznachrichten.deImunon reports 2024 EPS ($1.62) vs. ($2.16) last yearFebruary 27, 2025 | markets.businessinsider.comImunon reports immunogenicity and safety data from DNA plasmid vaccine trialFebruary 27, 2025 | msn.comImunon, Inc. (IMNN) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comIMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 StudyFebruary 27, 2025 | globenewswire.comImunon announces new analyses of results from Phase 1 trial of IMNN-101February 26, 2025 | markets.businessinsider.comIMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19February 26, 2025 | globenewswire.comIMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025February 20, 2025 | globenewswire.comImunon announces data from Phase 2 OVATION 2 Study of IMNN-001February 19, 2025 | markets.businessinsider.comIMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian CancerFebruary 19, 2025 | globenewswire.comImunon appoints Faller as Chief Medical OfficerFebruary 11, 2025 | markets.businessinsider.comIMUNON Appoints Douglas V. Faller, M.D.February 10, 2025 | globenewswire.comDonald P. Braun Purchases 25,000 Shares of Imunon, Inc. (NASDAQ:IMNN) StockJanuary 29, 2025 | insidertrades.comImunon director Donald Braun acquires $29,480 worth of sharesJanuary 28, 2025 | msn.comIMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…January 28, 2025 | msn.comImunon announces positive outcome of Type C CMC meeting with FDA on IMNN-001December 20, 2024 | markets.businessinsider.comImunon, Inc.: IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian CancerDecember 19, 2024 | finanznachrichten.deIMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian CancerDecember 19, 2024 | globenewswire.comImunon announces additional data from results from Phase 2 OVATION 2 studyDecember 11, 2024 | markets.businessinsider.comStrong Potential for Imunon’s IMNN-001 in Advanced Ovarian Cancer: Promising OVATION 2 Study ResultsDecember 11, 2024 | markets.businessinsider.comIMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001December 10, 2024 | globenewswire.comImunon Receives Buy Rating Amid Promising Phase 3 Trial Prospects for IMNN-001 in Advanced Ovarian CancerNovember 27, 2024 | markets.businessinsider.comIMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001…November 26, 2024 | msn.comIMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian CancerNovember 25, 2024 | globenewswire.comIMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer TrialNovember 11, 2024 | finance.yahoo.comImunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...November 8, 2024 | finance.yahoo.comImunon presents data from Phase 2 OVATION 2 clinical trialNovember 7, 2024 | markets.businessinsider.comImunon, Inc. (IMNN) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comImunon Announces Positive Data From Phase 2 Trial Of IMNN-001 In Advanced Ovarian Cancer, Stock DownNovember 7, 2024 | markets.businessinsider.comIMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual MeetingNovember 7, 2024 | globenewswire.comIMUNON Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 7, 2024 | globenewswire.comImunon (IMNN) Scheduled to Post Earnings on ThursdayImunon (NASDAQ:IMNN) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comImunon to present Phase 2 data of IMNN-001October 31, 2024 | markets.businessinsider.comIMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024October 31, 2024 | globenewswire.comIMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual MeetingOctober 30, 2024 | globenewswire.comImunon reports inducement grant under NASDAQ listing ruleOctober 8, 2024 | finance.yahoo.comIMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)October 7, 2024 | globenewswire.comImunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy"EF Hutton Acquisition Co. I upgraded shares of Imunon to a "strong-buy" rating in a research note on Monday.September 25, 2024 | marketbeat.comEF Hutton Initiates Coverage of Imunon (IMNN) with Buy RecommendationSeptember 24, 2024 | msn.com Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNN Media Mentions By Week IMNN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNN News Sentiment▼0.000.73▲Average Medical News Sentiment IMNN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNN Articles This Week▼11▲IMNN Articles Average Week Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RPTX News Today BDRX News Today ONCY News Today PEPG News Today IMRX News Today PDSB News Today SKYE News Today GANX News Today ICCC News Today CUE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
